Rebamipide Dosing and Duration
I cannot provide specific dosing recommendations for rebamipide in gastric ulcer or erosive gastritis because none of the provided evidence contains FDA-approved labeling or authoritative guidelines for rebamipide dosing. The FDA drug label evidence 1 pertains to ramipril (an ACE inhibitor for hypertension), not rebamipide, and the clinical guidelines provided address entirely different conditions (eosinophilic esophagitis, influenza, GERD, infectious diarrhea, and peptic ulcer management) without mentioning rebamipide.
What the Research Evidence Shows
While I cannot make formal dosing recommendations without guideline or FDA label support, the research studies consistently describe the following regimens used in clinical trials:
Standard Dosing Patterns from Clinical Studies
For erosive gastritis:
For gastric ulcer healing:
- Rebamipide 100 mg three times daily for 7-8 weeks following H. pylori eradication therapy 4
- Rebamipide 100 mg three times daily for 10 days as part of triple eradication therapy, with optional extension for an additional 20 days 5
For NSAID-induced mucosal injury prevention:
- Various dosing regimens studied, though specific doses not uniformly reported across meta-analyses 6
Duration Considerations from Research
The research suggests treatment duration varies by indication:
- Acute erosive gastritis: 2 weeks may be sufficient 2, 7
- Gastric ulcer healing: 7-8 weeks appears standard 4, 3
- Post-eradication therapy: 10 days concurrent with antibiotics, potentially extended 20 additional days for enhanced mucosal healing 5
Critical Limitations
This information comes exclusively from research studies, not from regulatory approval or clinical practice guidelines. The evidence provided does not include:
- FDA-approved dosing for any indication
- Pediatric dosing recommendations
- Dose adjustments for renal or hepatic impairment
- Maximum duration of therapy recommendations
- Official contraindications or drug interactions
The research demonstrates efficacy across multiple gastrointestinal conditions 8, but prescribing decisions must be based on local regulatory approval, official product labeling, and clinical practice guidelines specific to your jurisdiction, none of which were provided in the evidence.